The Vetr crowd upgraded its rating for Juno Therapeutics Inc JUNO on Monday from 4 stars (Buy), issued five days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 87 percent of Vetr user rating bullish.
Share price in the biotech company experienced a fairly substantial correction following Friday's earnings report that saw revenue exceed expectations to the tune of nearly $6 million, while EPS remained in the red, meeting estimates of $(0.71).
The underwhelming report resulted in a more than 8.5 percent drop for the stock on Friday. That continued into the next week and Juno finished today's trading day at $22.16, about $3.50 below its pre-earnings close.
Learn how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price is up at $27.94, which is still well below the average analyst target price of $34.50. Less than 2 percent of Vetr users are holding JUNO in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
